Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.4.3 (phospholipase C)
18,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Dispersed mouse pancreas acinar cells were prepared in which phosphatidylinositol had been labeled with myo[2-3H]inositol. During incubation with 0.3 microM cholecystokinin octapeptide (CCK-8) for 15 min, there was a loss of [3H]phosphatidylinositol radioactivity (23%) and a 3-fold gain in trichloroacetic acid-soluble radioactivity. Replacement of NaCl by up to 58 mM LiCl did not significantly affect the amount of CCK-8-stimulated [3H]phosphatidylinositol breakdown or the gain in acid-soluble radioactivity. However, in normal medium, the product of phosphatidylinositol breakdown was almost all inositol, whereas in Li+-containing medium, the product was almost all inositol 1-phosphate. Similar results were obtained with acetylcholine which, in the presence of Li+, gave a dose-responsive increase in inositol 1-phosphate over the concentration range of 0.1 to 10 microM. No increased accumulation of [3H]inositol diphosphate or [3H]inositol triphosphate was detected in stimulated cells. Time courses in the presence of Li+ indicated that the formation of inositol 1-phosphate preceded the formation of inositol. Addition of up to 50 mM myoinositol to the incubation medium showed no diluting effect on the amount of [3H]inositol 1-phosphate found. The accumulation of inositol 1-phosphate is presumably due to the known ability of Li+ to inhibit myoinositol 1-phosphatase. The results provide clear evidence that stimulated phosphatidylinositol breakdown involves a phospholipase C type of phosphodiesterase activity. 1.25 mM Li+ gave half-maximal inositol 1-phosphate accumulation. This is close to the range of plasma Li+ levels which is used therapeutically in psychiatric disorders. In unstimulated cells, [3H]inositol 1-phosphate accumulation in the presence of Li+ corresponded to a breakdown rate for [3H]phosphatidylinositol of 2 to 3%/h.
...
PMID:Lithium-induced accumulation of inositol 1-phosphate during cholecystokinin octapeptide- and acetylcholine-stimulated phosphatidylinositol breakdown in dispersed mouse pancreas acinar cells. 632 67

A calmodulin-Ca2+-stimulated cyclic nucleotide phosphodiesterase (EC 3.1.4.17) which hydrolyzed both cGMP and cAMP has been purified about 2000-fold from ovaries of the amphibian Xenopus laevis. Gel filtration through Sephadex G-200 indicated a molecular weight of 140,000. A single, major protein band of molecular weight 66,000 was observed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. In addition to the stimulation by calmodulin-Ca2+, the enzyme was activated 5- to 10-fold by proteolysis and by certain phospholipids. Trypsin activation of the enzyme caused a reduction in the native molecular weight to 90,000 and a loss of the capacity to be stimulated by calmodulin-Ca2+ or by phospholipids. The phosphodiesterase was stimulated by low concentrations (0.1 microgram/ml) of lysophosphatidylcholine and lysophosphatidylethanolamine. This response did not require calcium ions. Phosphatidylinositol, fatty acids, progesterone, and phospholipase C had little or no effect on activity. Simultaneous addition of 1 mM 2-chloro-10-(3-aminopropyl)phenothiazine and lysophosphatidylcholine to the enzyme did not diminish the stimulatory effect of the phospholipid. The activation of the enzyme by all three agents resulted in an increase in the maximum velocity of the reaction without significant modification of the apparent Km values for cGMP (5 microM) or cAMP (30 microM). It was suggested that trypsin removed an inhibitory domain from the enzyme and that calmodulin and phospholipids interact with this same domain, eliminating its capacity to inhibit the active center of the enzyme.
...
PMID:Properties of a cyclic nucleotide phosphodiesterase of amphibian oocytes that is activated by calmodulin and calcium, by tryptic proteolysis, and by phospholipids. 632 99

Vasopressin induced a transient increase of 50% in the total concentration of diacylglycerols (determined by g.l.c.) in isolated hepatocytes. The increase was maximal at 0.25 min, and the concentration of diacylglycerols in cells treated with vasopressin had returned to the basal value by 4 min. No change in the concentration of diacylglycerols was observed after the treatment of cells with glucagon. The dependency of this effect on the concentration of vasopressin was similar to that of the effect of the hormone on 45Ca2+ efflux measured at 0.1 mM extracellular Ca2+. Vasopressin increased the proportion of arachidonic acid and stearic acid and decreased the proportion of oleic acid present in the diacylglycerols. In hepatocytes prelabelled with [14C]arachidonic acid, vasopressin increased the amount of [14C]diacylglycerol. The effects of vasopressin on the total concentration of diacylglycerols and [14C]diacylglycerol were mimicked by an exogenous phospholipid phosphodiesterase (phospholipase C) from Clostridium perfringens. The results are consistent with the conclusion that the transient increase in diacylglycerols induced by vasopressin is caused by the rapid hydrolysis of both the phosphoinositides and one or more other phospholipids.
...
PMID:A transient increase in diacylglycerols is associated with the action of vasopressin on hepatocytes. 647 30

The fatty acid selectivity of cytosolic phospholipase C (phosphatidylinositol phosphodiesterase) from pig and human platelets towards phosphatidylinositol was evaluated. For this purpose, the relative conversion of rat liver phosphatidylinositol (enriched in stearate and arachidonate) and sheep liver phosphatidylinositol (enriched in stearate plus oleate and containing linoleate and arachidonate) was compared and, in addition, the fatty acid compositions of the diacylglycerol products were determined by gas-liquid chromatography. The cytosolic enzyme exhibited essentially complete specificity for phosphatidylinositol when choline-, ethanolamine-, serine-, or inositol-containing phospholipids labelled with [14C]stearate were tested as substrates. Similar percentage conversions of rat and sheep liver phosphatidylinositols to 1,2-diacylglycerol were found with phospholipase C from either pig or human platelets. Furthermore, the newly formed diacylglycerols and the unreacted phospholipid had fatty acid compositions which were very similar to the corresponding substrates. These results suggest that the phospholipase C from isolated platelet cytosol is highly selective towards phosphatidylinositol, but not with respect to the fatty acid composition of naturally occurring phosphatidylinositol. They also suggest that any preferential release of arachidonoyl diacylglycerol in stimulated human platelets is more likely controlled by compartmentation of the corresponding phosphatidylinositol precursor within platelet membranes and its availability, rather than directly by a marked enzyme preference for arachidonate-containing species.
...
PMID:Evaluation of the fatty acid selectivity of a phosphatidylinositol-specific cytosolic phospholipase C from pig and human platelets. 651 12

We examined the degradation of a labeled phosphatidylglycerol (PG) by fibroblasts from a normal control and a patient with Niemann-Pick (NP) disease. The control homogenate had both phospholipase A and phospholipase C activities toward PG, but NP cells had only phospholipase A. The PG phospholipase C of control fibroblasts was solubilized by sonication and freezing and thawing, was most active at pH 5.0, and was inhibited by Ca2-, detergents, sphingomyelin, and 5' AMP. Assay of PG phospholipase C in fibroblast cultures from NP patients with sphingomyelinase deficiency (three designated type A and four type B) confirmed absence of activity, whereas cultures from NP patients without sphingomyelinase deficiency (three designated type C and one with neurovisceral lipidoses and vertical supranuclear ophthalmoplegia) had activities close to those of normal controls. These findings substantiate previous observations of low phosphodiesterase activities in NP disease and suggest that the enzymatic function affected by the NP genes includes specificity toward PG and sphingomyelin. Deficiency of PG phospholipase C may explain the accumulation of bis(monoacylglycero)phosphate in NP disease.
...
PMID:Deficiency of phospholipase C acting on phosphatidylglycerol in Niemann-Pick disease. 668 61

Examination of release of labeled glyceride from 2-[1-14C]oleoyl phosphatidylcholine by a soluble extract of human fibroblasts confirmed the presence of phosphodiesterase which is stimulated strongly by sodium taurocholate. This activity was maximal at pH 4.5 and was inhibited by sphingomyelin and 5' AMP. Assay of the phosphatidylcholine phosphodiesterase activity in fibroblast cultures from patients with Niemann-Pick disease revealed a severe deficiency in those cultures also deficient in sphingomyelinase (3 type A and 4 type B) whereas assay of cultures from Niemann-Pick patients without sphingomyelinase deficiency (3 type C and 1 with neurovisceral lipidosis and vertical supranuclear ophthalmoplegia) gave activities similar to controls. The distribution of label in the products of the reactions catalyzed by both control and Niemann-Pick extracts indicates that the phosphodiesterase activity observed was phospholipase C and that phospholipase D was not involved. The close correlation of phosphatidylcholine phospholipase C and sphingomyelinase activities in the control and mutant fibroblasts strongly suggests that both activities are catalyzed by one enzyme. Various alterations in the regulation of the specificity of a multifunctional phospholipase C may underlie phenotypic variation in Niemann-Pick disease.
...
PMID:Deficiency of taurocholate-dependent phospholipase C acting on phosphatidylcholine in Niemann-Pick disease. 685 19

Pituitary adenylate cyclase-activating polypeptide (PACAP) acts via type I receptors in the pituitary to stimulate cAMP production. Gonadotropes are likely target cells for PACAP action, and we have recently shown alpha T3-1 cells, a clonal gonadotrope-derived cell line, to be PACAP responsive. Here we have explored the influence of GnRH on PACAP action in alpha T3-1 cells and show that PACAP38-stimulated cAMP production is inhibited by GnRH in both the presence and the absence of a phosphodiesterase inhibitor. This effect appears not to be Ca++ mediated but is mimicked by protein kinase C activation with phorbol 12-myristate 13-acetate. However, GnRH and phorbol 12-myristate 13-acetate do not inhibit binding of [125I]PACAP27 to intact alpha T3-1 cells, nor do they inhibit forskolin- or cholera toxin-stimulated cAMP accumulation, implying that the inhibitory effects are exerted at early stages in the PACAP receptor signaling pathway but distal to receptor occupancy. When cells were preincubated with PACAP38, extensive washing failed to prevent the stimulatory effect of the polypeptide presumably because of the slow rate of receptor-ligand dissociation. However, when the time course of PACAP38-stimulated effects on intracellular cAMP was assessed, the stimulatory effect of PACAP38 could be rapidly reversed by GnRH addition, and the inhibitory effect of GnRH was rapidly be reversed by a GnRH receptor antagonist. The data provide the first demonstration of cross-talk between phospholipase C and adenylate cyclase-activating peptides in gonadotrope-derived cells and establish the potential for hormonal modulation of PACAP action. We suggest that this inhibitory effect of GnRH might enable the releasing hormone to control the kinetics of cAMP signaling in gonadotropes in vivo.
...
PMID:Pituitary adenylate cyclase-activating polypeptide effects in pituitary cells: modulation by gonadotropin-releasing hormone in alpha T3-1 cells. 751 5

The effect of chronic exposure of DDT1-MF2 smooth muscle cells to the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) was investigated with regard to the dynamics of alpha-1-adrenergic receptors. After 48 hr of exposure to 750 microM IBMX, the magnitude of the maximal phospholipase C response to norepinephrine was increased approximately 2-fold and the potency of norepinephrine was increased almost 3-fold. Similar effects were noted for the response to ATP. The density of alpha-1-adrenergic receptors, as defined by [3H]-prazosin binding to membranes was increased 2-fold. In addition, chronic treatment with IBMX prevented agonist-induced desensitization of alpha-1-adrenergic receptors and enhanced the rate of receptor resensitization subsequent to desensitization by a combination of agonist and phorbol ester. These effects appear to be regulated by a cyclic AMP-dependent mechanism. Thus, chronic exposure of smooth muscle cells to phosphodiesterase inhibition may activate compensatory mechanisms that lead to enhanced sensitivity to contractile stimuli. The potential importance of such compensatory mechanisms in the treatment and etiology of smooth muscle dysfunction is briefly discussed.
...
PMID:3-Isobutyl-1-methylxanthine increases alpha-1-adrenergic receptor sensitivity and density in DDT1-MF2 smooth muscle cells. 752 8

We have previously shown that activation of the phosphatidyl-inositol/phospholipase C pathway could induce interleukin 6 (IL-6) release from U373MG human astrocytomes cells. We also found that, although interleukin 1 beta (IL-1 beta) did not activate phosphatidy-linositol turnover, it induced, a robust release of IL-6. In the present study, we examined the role of adenylate cyclase/cyclic 3',5'-adenosine monophosphate (cAMP) pathway in IL-6 release. Agents which mimicked (dibutyryl cAMP) or stimulated (isoproterenol and forskolin) cAMP formation were found to induce IL-6 release and their effects could be potentiated by 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor. On the other hand, in spite of its robust action on IL-6 release, IL-1 beta did not stimulate cAMP formation. Other possible signal transduction mechanisms involved in IL-1 beta-induced IL-6 release are discussed.
...
PMID:cAMP is not involved in interleukin-1-induced interleukin-6 release from human astrocytoma cells. 752 12

To study cross-talk mechanisms in rat pinealocytes, the role of tyrosine kinase or kinases in the regulation of adrenergic-stimulated cyclic AMP production was investigated. Both norepinephrine- and isoproterenol-stimulated cyclic AMP accumulation were increased by two distinct tyrosine kinase inhibitors, genistein or erbstatin, in a concentration-dependent manner. A similar increase was observed with two other inhibitors, tyrphostin B44 and herbimycin. In contrast, daidzein, an inactive analogue of genistein, was ineffective; whereas vanadate, a phosphotyrosine phosphatase inhibitor, reduced the adrenergic-stimulated cyclic AMP accumulation. The tyrosine kinase inhibitors were effective in potentiating the cholera toxin-or forskolin-stimulated cyclic AMP accumulation, indicating that their sites of action are at the postreceptor level. Neither an activator nor inhibitors of protein kinase C influenced the potentiation of the cyclic AMP responses by genistein, suggesting that the potentiation effect by tyrosine kinase inhibitors does not involve the phospholipase C/protein kinase C pathway. However, when the phosphodiesterase was inhibited by isobutylmethylxanthine, genistein failed to potentiate and vanadate did not inhibit the adrenergic-stimulated cyclic AMP accumulation, indicating that the phosphodiesterase is a probable site of action for these inhibitors. These results suggest that cyclic AMP metabolism in the pinealocytes is tonically inhibited by tyrosine kinase acting on the cyclic AMP phosphodiesterase.
...
PMID:Potentiation of agonist-stimulated cyclic AMP accumulation by tyrosine kinase inhibitors in rat pinealocytes. 756 54


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---